16 recruiting, 6 not yet recruiting, 4 active not recruiting, 2 completed. 28 Phase 2, 10 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 28 | Recruiting 16, Not yet recruiting 6, Active not recruiting 4, Completed 2 |
| Phase 1 | 10 | Recruiting 8, Completed 1, Not yet recruiting 1 |
Follow T-DXd: new trials by email Literature Review of T-DXd trials Research Report on T-DXd
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma Biospecimen Collection, Diagnostic Imaging Testing, Echocardiography Test - Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 31 | 2027-06-01 | 2026-10-22 |
| Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast Cancer Azeliragon, T-DXd - T-dxd Resistant HER2-Positive, HER2 Low Metastatic Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | The Methodist Hospital Research Institute | 27 | 2026-12-01 | 2026-08-25 |
| Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer Trastuzumab deruxtecan, Lovastatin - Breast Cancer, Advanced Breast Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 60 | 2026-11-30 | 2026-11-02 |
| A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer Fam-Trastuzumab Deruxtecan-Nxki - Colorectal Cancer, Adenocarcinoma of the Colon | Phase 2 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 27 | 2026-10-01 | 2026-10-01 |
| A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer Patritumab deruxtecan, Trastuzumab deruxtecan - Hormone Receptor Positive, HER2-low or HER2-ultralow | Phase 1 / Phase 2 | Recruiting | Daiichi Sankyo | 220 | 2026-09-17 | 2026-10-01 |
| Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 37 | 2026-06-17 | 2026-09-04 |
| Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer Trastuzumab Rezetecan for Injection (SHR-A1811), Trastuzumab Deruxtecan for Injection (T-DXd) - Advanced Breast Cancer | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 100 | 2026-06-01 | 2026-06-05 |
| SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study SHR-A1811, Pyrotinib, Capecitabine - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 100 | 2026-03-31 | 2026-02-18 |
| Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy Trastzumab Deruxtecan, Bevacizumab, Platinum Based Chemotherapy - Ovarian Cancer, Ovarian Carcinoma, Recurrent | Phase 2 | Recruiting | Yonsei University | 116 | 2026-02-26 | 2026-04-20 |
| Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management Digital Health Tools, T-DXd, Pertuzumab - Breast Cancer Stage IV | Phase 2 | Recruiting | SOLTI Breast Cancer Research Group | 300 | 2026-02-18 | 2026-03-27 |
| ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer Elacestrant, Trastuzumab Deruxtecan - Metastatic Breast Cancer, HER2 Low Breast Carcinoma | Phase 1 / Phase 2 | Recruiting | Kristina A. Fanucci | 65 | 2025-11-17 | 2026-06-10 |
| Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases T-DXd - Breast Cancer | Phase 1 / Phase 2 | Recruiting | Fudan University | 139 | 2025-05-12 | 2026-10-26 |
| Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 500 | 2025-03-18 | 2026-10-20 |
| TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd Trastuzumab Deruxtecan, Datopotamab Deruxtecan - Breast Cancer, HER2-low Breast Cancer | Phase 2 | Recruiting | Ana C Garrido-Castro, MD | 357 | 2024-10-29 | 2026-08-26 |
| Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer Trastuzumab deruxtecan, Afatinib - Stomach Neoplasm | Phase 1 / Phase 2 | Recruiting | Jeeyun Lee | 61 | 2024-09-30 | 2025-12-15 |
| T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer T-DXd, THP - HER2-positive Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 242 | 2024-09-01 | 2024-08-12 |
| The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer Nab-Paclitaxel, Paclitaxel, Docetaxel - Breast Cancer Female, Breast Cancer | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 72 | 2024-08-08 | 2026-08-06 |
| PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer Trastuzumab deruxtecan, Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection, Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection - HER2-positive Breast Cancer | Phase 2 | Active not recruiting | MedSIR | 165 | 2024-07-22 | 2026-04-29 |
| A Phase 1/2 Study of IAM1363 in HER2 Cancers IAM1363, Oral treatment with IAM1363 capsules or tablets, administered in combination with capecitabine + trastuzumab, Oral treatment with IAM1363 capsules or tablets, administered in combination with capecitabine + zanidatamab - HER2 Mutation-Related Tumors, HER2 | Phase 1 / Phase 2 | Recruiting | Iambic Therapeutics, Inc | 463 | 2024-03-25 | 2026-11-17 |
| A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors Trastuzumab deruxtecan, Bevacizumab - Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer) | Phase 2 | Active not recruiting | AstraZeneca | 127 | 2024-02-22 | 2026-09-03 |
Showing 20 of 28. Sign in to see all of them.
Breast Neoplasms (12) · Colorectal Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Neoplasm Metastasis (3) · Stomach Neoplasms (3) · Brain Neoplasms (2) · Colonic Neoplasms (2) · Pancreatic Neoplasms (2) · Rectal Neoplasms (2) · Adenocarcinoma (1) · Desmoplastic Small Round Cell Tumor (1) · Glioblastoma (1) · Lung Neoplasms (1) · Meningeal Carcinomatosis (1) · Neoplasm, Residual (1)
National Cancer Institute (NCI) (4) · AstraZeneca (3) · Daiichi Sankyo (2) · Fudan University (2) · Memorial Sloan Kettering Cancer Center (2) · Ana C Garrido-Castro, MD (1) · Dana-Farber Cancer Institute (1) · Iambic Therapeutics, Inc (1) · Jeeyun Lee (1) · Kristina A. Fanucci (1) · MedSIR (1) · NRG Oncology (1) · National Cancer Center Hospital East (1) · Peking University Cancer Hospital & Institute (1) · QuantumLeap Healthcare Collaborative (1)
United States (18) · South Korea (7) · Spain (7) · France (6) · Italy (5) · China (4) · Japan (4) · Belgium (3) · Germany (3) · Taiwan (3) · United Kingdom (3) · Australia (2) · Canada (2) · Netherlands (2) · Austria (1)
Alan L Ho (1) · Ana Garrido-Castro, MD (1) · Andreas N Saltos (1) · Andrew A Davis, MD (1) · Antonio Llombart-Cussac, MD (1) · Damon R Reed (1) · Funda Meric-Bernstam (1) · Hanfang Jiang (1) · Jeeyun Lee, Ph, MD (1) · John Heymach, M.D, Ph.D (1)
PMID 37870536, PMID 38351187, PMID 39116902, PMID 39261417, PMID 41213241, PMID 41487064, PMID 42131734, PMID 42135959
2023 (3), 2017 (1), 2025 (1), U10CA180868 (1), UM1CA186644 (1), UM1CA186688 (1), UM1CA186689 (1), UM1CA228823 (1)